A methylation-based prognostic signature in stage II colorectal patients: Considerations for clinical adoption
J Natl Cancer Inst
.
2023 Jan 10;115(1):8-11.
doi: 10.1093/jnci/djac184.
Authors
Paul B Romesser
1
2
,
Francisco Sanchez-Vega
3
4
,
J Joshua Smith
3
Affiliations
1
Colorectal Anal Cancer Service, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3
Colorectal Cancer Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
PMID:
36171662
PMCID:
PMC9830476
DOI:
10.1093/jnci/djac184
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
MeSH terms
Colorectal Neoplasms* / diagnosis
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / pathology
DNA Methylation*
Humans
Neoplasm Staging
Prognosis
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States
P30 CA008748/CA/NCI NIH HHS/United States
K08CA255574/BC/NCI NIH HHS/United States
R37 CA248289/NH/NIH HHS/United States
K08 CA255574/CA/NCI NIH HHS/United States
R37 CA248289/CA/NCI NIH HHS/United States